Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL

被引：8
|
作者：
Wang, Libing [1 ]
Du, Juan [2 ]
Huang, Aijie [1 ]
Tang, Gusheng [1 ]
Gong, Shenglan [1 ]
Cheng, Hui [1 ]
Zhang, Weiping [1 ]
Yang, Jianmin [1 ]
Wang, Jianmin [1 ]
Hu, Xiaoxia [1 ]
机构：
[1] Changhai Hosp, Inst Hematol, Dept Hematol, Shanghai 200433, Peoples R China
[2] Changzheng Hosp, Dept Hematol, Shanghai 200003, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 01期
基金：
中国国家自然科学基金;
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ADULT PATIENTS; IMATINIB; IMPACT; PLUS; MRD;
D O I：
10.1038/s41409-019-0514-4
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：245 / 248
页数：4
相关论文
共 50 条
  • [21] Allogeneic transplantation is not superior to chemotherapy in most patients over 40years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission
    Wolach, Ofir
    Stevenson, Kristen E.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Ballen, Karen K.
    Soiffer, Robert J.
    Antin, Joseph H.
    Neuberg, Donna S.
    Ho, Vincent T.
    Stone, Richard M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) : 793 - 799
  • [22] Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
    Giebel, Sebastian
    Labopin, Myriam
    Potter, Michael
    Poire, Xavier
    Sengeloev, Henrik
    Socie, Gerard
    Huynh, Anne
    Afanasyev, Boris V.
    Schanz, Urs
    Ringden, Olle
    Kalhs, Peter
    Beelen, Dietrich W.
    Campos, Antonio M.
    Masszi, Tamas
    Canaani, Jonathan
    Mohty, Mohamad
    Nagler, Arnon
    EUROPEAN JOURNAL OF CANCER, 2018, 96 : 73 - 81
  • [23] Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation
    Khabori, M. A.
    El-Emary, M.
    Xu, W.
    Guyatt, G.
    Galal, A.
    Kuruvilla, J.
    Lipton, J.
    Messner, H.
    Gupta, V.
    BONE MARROW TRANSPLANTATION, 2011, 46 (04) : 516 - 522
  • [24] Post-remission therapy with imatinib and HAM improve MRD before tansplant for patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL): Results of the GRAALL AFR03 study.
    Leguay, Thibaut
    Witz, Francis
    De Botton, Stephane
    Gabert, Jean
    Cayuela, Jean-Michel
    Macintyre, Elizabeth
    Preudhomme, Claude
    Fegueux, Nathalie
    Thomas, Xavier
    Cahn, Jean-Yves
    Escoffre, Martine
    Delannoy, Andre
    Ifrah, Norbert
    Dombret, Herve
    Pigneux, Arnaud
    BLOOD, 2006, 108 (11) : 532A - 532A
  • [25] Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide
    Piemontese, Simona
    Labopin, Myriam
    Choi, Goda
    Broers, Annoek E. C.
    Peccatori, Jacopo
    Meijer, Ellen
    Van Gorkom, Gwendolyn
    Rovira, Montserrat
    Cascon, Maria Jesus Pascual
    Sica, Simona
    Vydra, Jan
    Kulagin, Alexander
    Spyridonidis, Alexandros
    Nagler, Arnon
    Bazarbachi, Ali
    Savani, Bipin
    Brissot, Eolia
    Sanz, Jaime
    Mohty, Mohamad
    Ciceri, Fabio
    LEUKEMIA, 2024, 38 (09) : 2016 - 2022
  • [26] Allogeneic stem cell transplantation is the optimal post-remission therapy in minimal residual disease positive patients with acute myeloid leukemia
    Gianni, L.
    Buccisano, F.
    Maurillo, L.
    Del Poeta, G.
    Del Principe, I
    Ottaviani, I
    Sarlo, C.
    Ammatuna, E.
    Campagna, S.
    Imo Consalvo, M.
    Amadori, A.
    Venditti, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 69 - 69
  • [27] Allogencic stem cell transplantation can be an effective post-remission strategy for acute myeloid leukemia patients aged less than 60 years with core binding factor: A nation-wide retrospective study in Korea.
    Shin, Ho-Jin
    Chung, Joo Seop
    Kim, Hyioung-Joon
    Sohn, Sang Kyun
    Min, Yoo Hong
    Won, Jong-Ho
    Kim, Inho
    Lee, Je-Hwan
    Lee, Jae Hoon
    Jung, Chul Won
    Ahn, Jin Seok
    Lee, Kyoo-Hyung
    Joo, Young Don
    BLOOD, 2007, 110 (11) : 331A - 332A
  • [28] Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
    J Tanaka
    H Kanamori
    S Nishiwaki
    K Ohashi
    S Taniguchi
    T Eto
    H Nakamae
    K Minagawa
    K Miyamura
    H Sakamaki
    Y Morishima
    K Kato
    R Suzuki
    N Nishimoto
    K Oba
    N Masauzi
    Bone Marrow Transplantation, 2013, 48 : 1389 - 1394
  • [29] Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JS']JSHCT)
    Tanaka, J.
    Kanamori, H.
    Nishiwaki, S.
    Ohashi, K.
    Taniguchi, S.
    Eto, T.
    Nakamae, H.
    Minagawa, K.
    Miyamura, K.
    Sakamaki, H.
    Morishima, Y.
    Kato, K.
    Suzuki, R.
    Nishimoto, N.
    Oba, K.
    Masauzi, N.
    BONE MARROW TRANSPLANTATION, 2013, 48 (11) : 1389 - 1394
  • [30] Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Mizuta, Shuichi
    Yanada, Masamitsu
    Sugiura, Isamu
    Yagasaki, Fumiharu
    Yujiri, Toshiaki
    Takeuchi, Makoto
    Hatta, Yoshihiro
    Kimura, Yukihiko
    Ueda, Yasunori
    Kanamori, Heiwa
    Usui, Noriko
    Akiyama, Hideki
    Miyazaki, Yasushi
    Ohtake, Shigeki
    Jinnai, Itsuro
    Matsuo, Keitaro
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2008, 112 (11) : 176 - 177
12345